Dr Lal Pathlabs Ltd vs Yatharth Hospital Trauma Care Services Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Dr Lal Pathlabs Ltd is ₹ 1906 as of 30 Oct 15:30 . The P/E Ratio of Dr Lal Pathlabs Ltd changed from 77.4 on March 2021 to 43.6 on March 2026 . This represents a CAGR of -9.12% over 6 yearsThe P/E Ratio of Yatharth Hospital & Trauma Care Services Ltd changed from 31.3 on March 2024 to 33.9 on March 2026 . This represents a CAGR of 2.70% over 3 years The Market Cap of Dr Lal Pathlabs Ltd changed from ₹ 22565 crore on March 2021 to ₹ 22015 crore on March 2026 . This represents a CAGR of -0.41% over 6 yearsThe Market Cap of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 3582 crore on March 2024 to ₹ 5946 crore on March 2026 . This represents a CAGR of 18.40% over 3 years The revenue of Dr Lal Pathlabs Ltd for the Jun '26 is ₹ 829.6 crore as compare to the Mar '26 revenue of ₹ 726.7 crore. This represent the growth of 14.16% The revenue of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 397.01 crore as compare to the Mar '26 revenue of ₹ 348.67 crore. This represent the growth of 13.86% The ebitda of Dr Lal Pathlabs Ltd for the Jun '26 is ₹ 279.4 crore as compare to the Mar '26 ebitda of ₹ 210.8 crore. This represent the growth of 32.54% The ebitda of Yatharth Hospital & Trauma Care Services Ltd for the Jun '26 is ₹ 96.04 crore as compare to the Mar '26 ebitda of ₹ 87.02 crore. This represent the growth of 10.37% The net profit of Dr Lal Pathlabs Ltd changed from ₹ 107.8 crore to ₹ 170.5 crore over 9 quarters. This represents a CAGR of 22.60% The net profit of Yatharth Hospital & Trauma Care Services Ltd changed from ₹ 30.38 crore to ₹ 45.42 crore over 9 quarters. This represents a CAGR of 19.57% The Dividend Payout of Dr Lal Pathlabs Ltd changed from 59.51 % on March 2021 to 67.59 % on March 2026 . This represents a CAGR of 2.14% over 6 yearsThe Dividend Payout of Yatharth Hospital & Trauma Care Services Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Dr Lal Pathlabs Ltd

Dr. Lal PathLabs Limited was incorporated as a Private Limited Company with the name Dr. Lal PathLabs Private Limited', on February 14, 1995 at Delhi.
The business of the Partnership Firm, Central Clinical Laboratory was undertaken by the Company.
The Company converted into a Public Limited Company and name of the Company was changed to Dr. Lal PathLabs Limited' vide fresh Certificate of Incorporation granted by the RoC on August 19, 2015. Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres.
Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

About Yatharth Hospital & Trauma Care Services Ltd

Yatharth Hospital & Trauma Care Services Limited was formerly incorporated as a Private Limited Company in Delhi dated February 28, 2008.
On November 3, 2021, the status converted into a Public Company and name of the Company was changed to Yatharth Hospital & Trauma Care Services Limited' on November 18, 2021 issued by the RoC. Yatharth Hospitals and Trauma Care Services Limited is a network of super speciality hospitals across Delhi National Capital Region (NCR) and Madhya Pradesh, capitalising on the robust healthcare infrastructure in these regions to serve a wide patient base in need of tertiary care. The Company operate three super specialty hospitals in Delhi NCR, i.e., at Greater Noida, Uttar Pradesh.
The super speciality tertiary care hospital currently operates with 400 beds, including 112 critical care beds and 9 modular operation theatres, among other surgical facilities.

FAQs for the comparison of Dr Lal Pathlabs Ltd and Yatharth Hospital & Trauma Care Services Ltd

Which company has a larger market capitalization, Dr Lal Pathlabs Ltd or Yatharth Hospital & Trauma Care Services Ltd?

Market cap of Dr Lal Pathlabs Ltd is 31,997 Cr while Market cap of Yatharth Hospital & Trauma Care Services Ltd is 8,942 Cr

What are the key factors driving the stock performance of Dr Lal Pathlabs Ltd and Yatharth Hospital & Trauma Care Services Ltd?

The stock performance of Dr Lal Pathlabs Ltd and Yatharth Hospital & Trauma Care Services Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Lal Pathlabs Ltd and Yatharth Hospital & Trauma Care Services Ltd?

As of October 31, 2026, the Dr Lal Pathlabs Ltd stock price is INR ₹1906.3. On the other hand, Yatharth Hospital & Trauma Care Services Ltd stock price is INR ₹928.05.

How do dividend payouts of Dr Lal Pathlabs Ltd and Yatharth Hospital & Trauma Care Services Ltd compare?

To compare the dividend payouts of Dr Lal Pathlabs Ltd and Yatharth Hospital & Trauma Care Services Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.